Navigation Links
U.S. Genomics Inc. Receives $4.5 Million Investment from BD

- Enters Strategic Collaboration for Development of Novel Infectious

Disease Diagnostic Platform -

WOBURN, Mass., Sept. 23 /PRNewswire/ -- U.S. Genomics today announced it has received a $4.5 million equity investment from BD (Becton, Dickinson and Company) and that the companies have entered into a strategic collaboration for development of a novel infectious disease diagnostic platform. The collaboration will focus on application of U.S. Genomics' DirectLinear Analysis(TM) technology (DLA) for the detection of a wide range of infectious organisms in a single molecular diagnostic test. A diagnostic platform based on DLA has the potential to provide information to physicians concerning pathogen identity, virulence and drug resistance within hours, as opposed to the multi-day techniques such as culturing, plating, and staining that are done today.

U.S. Genomics has invested in excess of $50 million in DLA technology, which integrates novel labeling strategies, advanced microfluidics and optical engineering to enable pathogens to be identified by rapidly analyzing individual DNA molecules present in a clinical sample. The technology is capable of simultaneously detecting a broad range of infectious organisms in a single diagnostic test. A diagnostic test based on DLA has the potential to provide clinicians and doctors' information important for patient health, such as which drugs a specific pathogen may be resistant to, and which drugs could be used for most effective patient treatment.

"We are very pleased to enter into this strategic relationship with BD," said John J. Canepa, U.S. Genomics' CEO. "BD is the clear market leader in clinical microbiology and their deep experience in product development is an ideal complement to our innovative DLA technology and strong research team. We share the goal of establishing a new, faster, more accurate capability for microbial diagnostics, based on genotype, leading to more effective patient treatment and better outcomes."

DLA technology, developed with support from venture capital investors, NSF, DARPA, and the U.S. Department of Homeland Security (DHS), also has the potential to be applied in applications such as patient screening, hospital monitoring, epidemiology and forensics. U.S. Genomics currently has an extremely sensitive and accurate sensor for detection of biological threats in development under the DHS Bioagent Autonomous Network Detector program. Similar precision is required in hospital settings, where regulations may restrict reimbursement for costs associated with certain infections that occur as a result of hospital procedures. DLA has the potential to rapidly and accurately resolve whether a patient who became sick during a hospital stay was infected with a known hospital-based organism, or a strain not previously seen.

"We see tremendous potential for application of DLA technology," Canepa continued. "Working closely with BD on this collaboration, we plan to prioritize development efforts toward the multi-billion dollar infectious disease testing market. Further, the flexibility of the DLA technology to address a wide range of sample types creates future opportunities for U.S. Genomics to expand into significant new application areas, such as bio- security, bio-surveillance, and environmental and food safety testing."

About U.S. Genomics, Inc.

U.S. Genomics is pioneering single molecule biology technologies for diagnostics and biodefense applications by combining advanced microfluidics, optical engineering, and novel labeling strategies. Using its DNA mapping technology, the Company is developing sophisticated biological sensors for the detection and identification of pathogens and biomarkers in the air and other biologically relevant materials. The Company's biodefense focus on airborne pathogens has been funded in part by contracts from the U.S. Department of Homeland Security Science and Technology Directorate. U.S. Genomics' portfolio of products will further a greater understanding of genetics and disease pathways leading to more effective use of therapeutics, and a range of diagnostics, and biodefense applications. For more information, please visit

SOURCE U.S. Genomics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
2. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
3. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
4. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
5. ( Announces Upcoming Interview With CEO of DNAPrint Genomics
6. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
7. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
8. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
9. BioNanoatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
10. BioNanomatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
11. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
Post Your Comments:
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... Calif. , June 23, 2016  The Prostate Cancer Foundation ... increasingly precise treatments and faster cures for prostate cancer. Members of the Class ... across 15 countries. Read More About the Class of ... ... ...
(Date:6/23/2016)... ... , ... In a new case report published today in STEM CELLS Translational ... lymphedema after being treated for breast cancer benefitted from an injection of stem cells ... this debilitating, frequent side effect of cancer treatment. , Lymphedema refers to ...
Breaking Biology Technology:
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/31/2016)...   LegacyXChange, Inc. ... LegacyXChange is excited to release its first ... be launched online site for trading 100% guaranteed authentic ... also provide potential shareholders a sense of the value ... industry that is notorious for fraud. The video is ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
Breaking Biology News(10 mins):